TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MUVON Therapeutics Appoints Dr. Christine Günther as Chief Technology Officer

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Dr. Deana Mohr
MUVON Therapeutics Appoints Dr. Christine Günther as Chief Technology Officer

MUVON Therapeutics announced positive Phase 2 clinical trial results for a novel muscle precursor cell therapy treating stress urinary incontinence, demonstrating high statistical significance and an 87% responder rate. The company also appointed Dr. Christine Günther as Chief Technology Officer to advance their regenerative medicine platform.

Insights
DHR   neutral

Listed as a key market player with potential growth opportunities in virtual biopsy technologies


EVO   neutral

Mentioned as a previous workplace for Dr. Günther with no specific company performance details